. Two Proposed Mechanisms for Islet ␤ Cell Destruction in Autoimmune Diabetes potent synergistic effects when in combination, and that by transfer experiments infusing polyclonal populations of effector T cells from diabetic NOD mice into irradiated certain of them are active, sometimes differentially, as either membrane or soluble forms. Also debated is at NOD versus NOD lpr/lpr recipients. The possibility that distinct mechanisms of ␤ cell what point the ␤ cells, themselves, enter the process ultimately leading to destruction: i.e., are they induced death might reign in the different diabetes models is underlined by recent observations made by other to synthesize certain of these mediators, hastening their own death? Interestingly, it has been reported that in groups. Zinkernagel, Hengartner, and colleagues have studied a model of autoimmune diabetes based on a vitro incubation of islets with certain cytokines leads to destruction of ␤ cells preferentially, providing a potential transgenic mouse line that expresses the glycoprotein of lymphocytic choriomeningitis virus (LCMV) specifiexplanation for the ␤ cell specificity of killing during diabetes, although this has been disputed. At present, cally in islet ␤ cells (Ohashi et al., 1991) . These mice are free of pathogenesis until infected with LCMV, when we are far from being able to draw a coherent picture of the events immediately preceding ␤ cell death during they develop rampant insulitis and diabetes. By crossing in a null mutation of the perforin gene, this group demonautoimmune attack. It will probably turn out that they can die by multiple means during the development of strated that their diabetes model is dependent on perforin-mediated cytotoxicity (Kä gi et al., 1996) , consistent diabetes and this could evolve through the course of disease.
with the fact that CD8 ϩ T cells are known to be the primary effector cells. Evidence that perforin was actuThis issue of Cell brings new information on this important matter. Chervonsky et al. (1997 [this issue of Cell]) ally playing its role at the stage of ␤ cell destruction was two-fold: (1) that only diabetes, not insulitis, was report experiments suggesting a role for Fas/Fas ligand (FasL) interactions in ␤ cell death in at least one form affected; and (2) that activated T cells from a TCR tg mouse line expressing an LCMV glycoprotein-specific of autoimmune diabetes. Three points are most relevant. First, NOD lpr/lpr mice, deficient in Fas expression be-TCR and also carrying the perforin mutation could transfer insulitis but not diabetes into wild-type recipients, cause of an incapacitating mutation in the fas gene did not develop spontaneous diabetes. Second, transfer of while cells from TCR tg littermates not bearing the mutation transferred both. Katz and colleagues have argued a particular NOD-derived, islet-reactive CD8 ϩ T cell clone (Wong et al., 1996) into young, irradiated NOD for the importance of still another mediator of ␤ cell death on the basis of results with a third diabetes model animals led to diabetes several days later, but a parallel transfer into NOD lpr/lpr recipients, did not provoke dis- (Pakala et al., 1997) . These experiments consisted of grafting islets from wild-type or various mutant mice ease. Transfer into animals engineered to express FasL constitutively on islet ␤ cells promoted diabetes unusuinto animals previously treated with streptozotocin to induce diabetes, and monitoring the integrity of the graft ally rapidly. Third, after transfer of the CD8 ϩ T cell clone into NOD mice, expression of Fas was rapidly induced over time. They found that islet grafts from wild-type mice or mutants lacking Fas, the ␣ chain of the IFN␥ on ␤ cells. These data provide strong evidence that Fas is a major mediator of ␤ cell death in this CD8 ϩ T cell receptor (R), or TNF-R2 were destroyed, while those from mutants devoid of TNF-R1 survived. This would transfer model of diabetes. It is not yet clear whether Fas-mediated death plays an important role in the sponseem to implicate a TNF/TNF-R1 interaction in the death of ␤ cells in this model, in line with the many reports taneous NOD model. The significance of the reported block in spontaneous diabetes in NOD lpr/lpr mice is implicating TNF␣ in the progression to diabetes in NOD mice (see discussion in Sarvetnick, 1996) . obscured by the known pleiotropic effects of the fas gene mutation-e.g., lymphoadenopathy, dysregulation So the picture we have at the moment is a cloudy one: data from three different diabetes models implicatof T cell populations, polyclonal B cell stimulation, strong constitutive up-regulation of FasL on lymphoing three distinct death effector systems-Fas/FasL, perforin, and TNF/TNF-R1-and not yet clearly indicatcytes (Chu et al., 1995 , and references therein). This problem could have been circumvented at least partially ing which of them (or others) are most important in the cal parameters (Bach, 1994) , and thus diabetes in man Immunol. 99, 6380. could be a set of related disorders with possible differ- Sarvetnick, N. (1996) . J. Exp. Med. 184, 1597 -1600 ences in inciting antigen, primary effector cell type, and, Spencer, D.M. (1996) . Trends Genet. 12, 181-187.
most relevant here, mechanism of ␤ cell destruction. It Tisch, R., and McDevitt, H. (1996) . Cell 85, 291-297.
is not known at present which of the mouse models Vaux, D.L., and Strasser, A. (1996) . Proc. Natl. Acad. Sci. USA 93, will prove the best for studying which of the human 2239-2244. variations. Neither is it known whether islet grafts are Wang, B., Gonzalez, A., Benoist, C., and Mathis, D. (1996) . Eur. J. subject to the same or different mechanisms of destruc- Immunol. 26, 1762 Immunol. 26, -1769 tion, an important question given the increasing interest Wong, F.S., Visintin, I., Wen, L., Flavell, R.A., and Janeway, C.A.
in using islet xenografts to attenuate disease. (1996) . J. Exp. Med. 183, [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] Although this is clearly a complicated issue, and the data reported so far suggest that its resolution will be complex, it is an issue well worth tackling because of the obvious therapeutic implications: the potential to engineer death-defying ␤ cells, an achievement which could significantly advance islet graft technology. One might attempt to block the different candidate death effector molecules one by one, and in combination, in the various mouse models. This could be achieved by treatment with the appropriate blocking reagents (MAbs, soluble receptors), by introducing the relevant null gene mutations or dominant negative mutants in a time-controlled fashion and specifically on islet ␤ cells, or only on the relevant attacking population of lymphocytes. (Wholesale knockout or transgenic approaches to manipulate such molecules have pleiotropic effects, and would be difficult to unravel.) The technology to accomplish this is available, if heavy (reviewed in Spencer, 1996) . Even more rigor and ingenuity will need to be applied to the human system. Although correlations between enhanced expression of particular death effector molecules and autoimmune destruction (e.g., Dowling et al., 1996; Giordano et al., 1997) are tantalizing, they can not be taken as proof of causality. Here too, other strategies have to be devised-for example, more effectively exploiting the potential of humanized severe combined immunodeficiency (SCID) mice (Mö ller, 1991) .
Given the importance of the task to be accomplished, the difficulties raised above should not be viewed as encumbrances, but as stimuli.
